<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Kidney disease associated with hepatitis B virus infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Kidney disease associated with hepatitis B virus infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Kidney disease associated with hepatitis B virus infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tak-Mao Chan, MD, DSc, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna SF Lok, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adrian M Di Bisceglie, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with hepatitis B virus (HBV) may be associated with a variety of kidney diseases [
         <a href="#rid1">
          1-3
         </a>
         ]. The three most common types of kidney disease resulting from HBV infection are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Membranous nephropathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Membranoproliferative glomerulonephritis (MPGN)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyarteritis nodosa (PAN)
        </p>
        <p>
        </p>
        <p>
         In addition, HBV infection has been associated with mesangial proliferative glomerulonephritis, immunoglobulin A (IgA) nephropathy, crescentic glomerulonephritis, focal segmental glomerulosclerosis (FSGS), minimal change disease, and amyloidosis, although the causative role of HBV has been debated for some of these conditions.
        </p>
        <p>
         This topic provides an overview of types of kidney disease associated with HBV infection, as well as the diagnosis and management of such patients. Additional discussions of HBV in patients receiving hemodialysis and in patients undergoing kidney transplantation are presented elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1931.html" rel="external">
          "Hepatitis B virus and dialysis patients"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7354.html" rel="external">
          "Kidney transplantation in adults: Hepatitis B virus infection in kidney transplant recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1340265">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney disease associated with HBV infection most commonly occurs in endemic areas. In these areas, infection is more likely to occur during infancy and early childhood, which increases the probability of becoming a chronic carrier [
         <a href="#rid4">
          4
         </a>
         ]. By comparison, the frequency of HBV-related kidney disease is low in patients born in the United States and western Europe due to the lower prevalence of chronic HBV infection in general and a lower likelihood of childhood infection [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3630.html" rel="external">
          "Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Epidemiology of chronic HBV'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5943.html" rel="external">
          "Clinical manifestations and diagnosis of hepatitis B virus infection in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The widespread use of hepatitis B vaccination has decreased the incidence of HBV-related membranous nephropathy and membranoproliferative glomerulonephritis (MPGN), providing evidence of the probable etiologic role of HBV [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">
          "Hepatitis B virus immunization in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1340332">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HBV-related kidney disease are positive for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) and, in those with membranous nephropathy, hepatitis B e antigen (HBeAg). Although some patients with HBV-related kidney disease have a history of active hepatitis, a large proportion of patients have only mild to moderate elevations in serum aminotransferases.
        </p>
        <p>
         The pathogenetic role of HBV infection has been documented primarily by the demonstration of hepatitis B antigen-antibody complexes in the kidney lesions via immunofluorescence microscopy, including deposition of HBeAg in membranous nephropathy [
         <a href="#rid1">
          1,7,8
         </a>
         ]. The relationship between HBV variants (eg, precore and core promoter mutations) that prevent or decrease HBeAg production (despite active viral replication by DNA testing) and kidney disease has not been well described. (See
         <a class="medical medical_review" href="/z/d/html/3639.html" rel="external">
          "Clinical significance and molecular characteristics of common hepatitis B virus variants", section on 'Precore and core promoter variants'
         </a>
         .)
        </p>
        <p>
         The pathogenesis of HBV-associated glomerular diseases has been attributed to the deposition of immune complexes, which trigger downstream inflammatory pathways. HBV DNA and HBV RNA have been localized to glomerular and tubular cells in affected patients; however, the role of these viral nucleic acids in the development of kidney injury remains to be confirmed [
         <a href="#rid9">
          9,10
         </a>
         ]. There is evidence that the virus may directly trigger pathological processes in the kidney. As an example, purified HBV can induce human glomerular mesangial cell proliferation and expression of type IV collagen [
         <a href="#rid11">
          11
         </a>
         ]. HBV X protein, which regulates HBV transcription and replication, can modulate signaling pathways and has been shown to induce a proinflammatory phenotype and stimulate epithelial-mesenchymal transition in kidney tubular epithelial cells [
         <a href="#rid12">
          12-15
         </a>
         ]. Data from single-cell RNA sequencing of kidney biopsies showed increased gene activation related to extracellular matrix formation in podocytes and inflammatory pathway and apoptotic signaling pathway gene activation in endothelial cells [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TYPES OF KIDNEY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The kidney diseases most commonly associated with HBV infection include membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), and polyarteritis nodosa (PAN) [
         <a href="#rid1">
          1,2,7
         </a>
         ]. In addition, HBV infection has less commonly been associated with other kidney lesions such as mesangial proliferative glomerulonephritis [
         <a href="#rid9">
          9,17
         </a>
         ], IgA nephropathy [
         <a href="#rid18">
          18
         </a>
         ], focal segmental glomerulosclerosis (FSGS) [
         <a href="#rid19">
          19
         </a>
         ], minimal change disease [
         <a href="#rid20">
          20
         </a>
         ], and amyloidosis [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         In addition to specific forms of glomerular diseases, HBV infection is associated with increased incidence and prevalence rates of chronic kidney disease (CKD) in endemic regions such as Taiwan, China, and South Korea [
         <a href="#rid22">
          22-24
         </a>
         ]. Analysis of nationwide health insurance data showed that antiviral treatment with nucleoside/nucleotide analogs was associated with a reduced risk of developing end-stage kidney disease in patients with CKD and HBV infection, with 16-year cumulative rates of 10.1 percent and 2.2 percent in the untreated and antiviral-treated populations, respectively [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         The discussion below focuses on the relationship of HBV to the most commonly associated kidney conditions. The clinical manifestations of these three diseases are discussed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">
          "Membranous nephropathy: Pathogenesis and etiology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3055.html" rel="external">
          "Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Membranous nephropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         HBV-associated secondary membranous nephropathy, as with other forms of membranous nephropathy, usually presents with proteinuria, which can be in the nephrotic range. Compared with patients who have idiopathic or primary membranous nephropathy, patients with HBV-associated membranous nephropathy are more likely to have microscopic hematuria and lower complement levels [
         <a href="#rid26">
          26
         </a>
         ]. The histologic presence of mesangial cell proliferation or mesangial or subendothelial immune deposits, in addition to the typical subepithelial localization, may be a clue to suggest secondary rather than primary membranous nephropathy.
        </p>
        <p>
         The phospholipase A2 receptor (PLA2R) has been implicated as the major antigen involved in the pathogenesis of primary membranous nephropathy (see
         <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">
          "Membranous nephropathy: Pathogenesis and etiology", section on 'Phospholipase A2 receptor'
         </a>
         ). Several studies have shown a low prevalence of anti-PLA2R antibodies and/or PLA2R staining of the immune deposits in HBV-associated membranous nephropathy. However, one retrospective study of 39 Chinese patients with hepatitis B-associated membranous nephropathy found that 64 percent of cases exhibited strong PLA2R staining of immune deposits [
         <a href="#rid27">
          27
         </a>
         ]. Staining for the hepatitis B surface antigen (HBsAg) colocalized with PLA2R within the deposits. Among the six patients for whom serum was available, all were positive for anti-PLA2R antibodies. In another report that included 50 patients with HBV-associated membranous nephropathy (and 56 patients with primary membranous nephropathy), four patients (8 percent) tested positive for anti-PLA2R antibodies in serum and five patients (10 percent) were positive for PLA2R in the kidney tissue [
         <a href="#rid28">
          28
         </a>
         ]. The association between hepatitis B infection and PLA2R-positive membranous nephropathy needs to be validated by further studies.
        </p>
        <p>
         It has been proposed that the deposition of hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe) immune complexes in the subepithelial region of the glomerular basement membrane is pivotal to disease pathogenesis [
         <a href="#rid1">
          1,7,8,29
         </a>
         ]. HBV-associated membranous nephropathy is more common in children and resolves spontaneously in many cases, usually in association with seroconversion from HBeAg to anti-HBe [
         <a href="#rid7">
          7
         </a>
         ]. By contrast, spontaneous resolution is relatively uncommon in adults, and some patients show progressive kidney deterioration over time [
         <a href="#rid2">
          2,8,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">
          "Membranous nephropathy: Pathogenesis and etiology", section on 'Etiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Membranoproliferative glomerulonephritis (MPGN)
         </span>
         <span class="headingEndMark">
          —
         </span>
         HBV-associated MPGN, as with other forms of MPGN, presents with hematuria (often with dysmorphic red blood cells and/or red blood cell casts), variable degrees of proteinuria, reduced glomerular filtration rate (GFR), and hypertension. The deposition of circulating antigen-antibody complexes in the mesangium and subendothelial space characterizes the MPGN associated with HBV. Both HBsAg and HBeAg deposition have been implicated in this disorder, although their exact role remains uncertain [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3055.html" rel="external">
          "Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis", section on 'Infections'
         </a>
         .)
        </p>
        <p>
         Compared with hepatitis C infection, HBV infection is a rare cause of mixed cryoglobulinemia, which can be associated with MPGN [
         <a href="#rid31">
          31-33
         </a>
         ]. In one series of 12 patients with HBV-associated cryoglobulinemia, all patients had nephrotic-range proteinuria and microscopic hematuria, and nine (75 percent) had impaired kidney function [
         <a href="#rid33">
          33
         </a>
         ]. A purpuric rash was present in more than one-half of the patients (58 percent), and all patients had evidence of hypocomplementemia and were positive for rheumatoid factor. Histologic features of MPGN were present in the kidney biopsies of all patients; only three patients had glomerular deposits of HBsAg, hepatitis B core antigen (HBcAg), or HBeAg. One-half of the patients died or developed end-stage kidney disease during follow-up despite having received various immunosuppressive and antiviral treatments. (See
         <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">
          "Overview of kidney disease associated with hepatitis C virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Polyarteritis nodosa (PAN)
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAN is a necrotizing vasculitis affecting small- and medium-sized blood vessels that frequently involves multiple organs; kidney involvement leads to variable degrees of reduced GFR and hypertension. The clinical features of HBV-associated PAN are similar to idiopathic PAN. (See
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         .)
        </p>
        <p>
         HBV-associated PAN typically occurs within four months after the onset of HBV infection [
         <a href="#rid34">
          34
         </a>
         ]. The presence of HBV-associated disease is suggested by the findings of HBsAg, HBeAg, and HBV DNA (an indicator of viral replication) in the serum. The deposition of circulating antigen-antibody immune complexes in the vessel wall triggers downstream inflammatory processes [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HBV-associated kidney disease should be suspected in patients with acute or chronic HBV infection who present with clinical and/or laboratory features suggestive of glomerular disease (eg, proteinuria and/or hematuria, acute kidney injury [AKI] or deterioration in kidney function, with or without hypertension and/or edema). It is particularly important to consider this diagnosis in patients from endemic areas, where both acute and chronic HBV infection are more prevalent. A kidney biopsy is often required to confirm the presence of an underlying glomerular process, although a different tissue site may be biopsied to confirm polyarteritis nodosa (PAN). (See
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
         In addition, a diagnosis of HBV-associated kidney disease should be considered in all patients with unknown HBV status who have evidence of nephrotic syndrome or glomerulonephritis or are found on kidney biopsy to have histologic evidence of membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), or PAN. Such patients should be tested for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) as part of their initial evaluation. If either is positive, additional testing for hepatitis B surface antibody (anti-HBs), hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe), and HBV DNA should be performed as appropriate to ascertain the viral replicative state. Concurrent infection with hepatitis C virus (HCV) or HIV should be considered and investigated as appropriate. (See
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">
          "Hepatitis B virus: Clinical manifestations and natural history", section on 'Phases of chronic HBV infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">
          "Screening and diagnosis of chronic hepatitis C virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">
          "Screening and diagnostic testing for HIV infection"
         </a>
         .)
        </p>
        <p>
         A presumptive diagnosis of HBV-associated kidney disease can be made in patients who are HBsAg positive and have biopsy-proven membranous nephropathy, MPGN, or PAN [
         <a href="#rid1">
          1,2
         </a>
         ], particularly if the patient is a child from an endemic area or an adult without another identifiable cause for the kidney disease. Such patients are often HBeAg positive. However, confirming the etiologic role of HBV in any of these disorders may, at times, be difficult, since the detection of viral antigen deposition in the kidney requires techniques that may not be available in many clinical settings. In addition, the presence of viral antigens in the kidney tissue may be coincidental rather than indicative of a causal relationship [
         <a href="#rid7">
          7
         </a>
         ]. Proof that HBV is the primary cause of the kidney disease can only be provided by improvement in the kidney disease with antiviral therapy and viral suppression.
        </p>
        <p>
         Diagnosing HBV-associated kidney disease is important because therapy with glucocorticoids, cytotoxic, or immunomodulatory agents, which are common therapies for primary forms of the above disorders, may not be beneficial in patients with HBV-associated kidney disease and may lead to reactivation of HBV replication, hepatitis flares, and liver failure if used without antiviral therapy.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of HBV-associated kidney diseases consists of antiviral therapy in most patients. This recommendation is consistent with treatment guidelines produced by Kidney Disease: Improving Global Outcomes (KDIGO) [
         <a href="#rid35">
          35
         </a>
         ]. By contrast, immunosuppressive therapy, with or without plasmapheresis, is used only in select patients (eg, rapidly progressive glomerulonephritis [RPGN] or polyarteritis nodosa [PAN] with severe manifestations), and when it is administered, it should always be used in combination with antiviral therapy.
        </p>
        <p>
         The limited data on the treatment of HBV-associated kidney diseases are based upon small case series and clinical trials. In addition, antiviral therapy in children and adults with HBV-associated kidney disease differs because the natural history of such diseases also differs.
        </p>
        <p class="headingAnchor" id="H1340634">
         <span class="h2">
          Antiviral therapy
         </span>
        </p>
        <p class="headingAnchor" id="H1340671">
         <span class="h3">
          Indications for antiviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend antiviral therapy for patients with HBV-associated kidney disease and detectable serum HBV DNA or positive hepatitis B e antigen (HBeAg). This recommendation is based primarily upon data from observational studies and uncontrolled trials that suggest antiviral therapy is associated with reduced proteinuria [
         <a href="#rid2">
          2,8,17,30,36-48
         </a>
         ].
        </p>
        <p>
         The following examples illustrate the quality of the data:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective report from the National Institutes of Health (NIH) evaluated 15 adults (10 with membranous nephropathy, four with membranoproliferative glomerulonephritis [MPGN], and one in whom kidney biopsy was not available) who were treated with 5 million units of
         <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">
          interferon alfa-2b
         </a>
         subcutaneously daily for 16 weeks [
         <a href="#rid38">
          38
         </a>
         ]. Eight responded with seroconversion of HBeAg to hepatitis B e antibodies (anti-HBe) and a reduction of HBV DNA to undetectable levels by hybridization assay. In seven patients, this was accompanied by gradual disappearance of proteinuria. Responders had lower baseline HBeAg and HBV DNA levels than nonresponders. In responders, remission persisted for a long period after therapy was discontinued. Patients with membranoproliferative disease appeared less responsive to treatment. The dose of interferon alfa-2b was lowered in seven patients due to side effects (fatigue or anemia). In two patients, therapy was discontinued (one patient had intractable fatigue, and the other had a seizure).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other studies that examined interferon alfa for HBV-associated kidney disease reported sustained seroconversion of HBeAg to anti-HBe in 38 to 80 percent of patients and remission of proteinuria in 25 to 100 percent of patients [
         <a href="#rid17">
          17,30,39,40
         </a>
         ].
         <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">
          Interferon alfa-2b
         </a>
         was discontinued by its manufacturer in 2019.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ten adult patients with HBV-associated membranous nephropathy were treated with the nucleoside analog
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         and were compared with 12 historical controls who had the same diagnosis but were not treated with lamivudine [
         <a href="#rid46">
          46
         </a>
         ]. Treatment with lamivudine was associated with disappearance of HBV DNA and reduction of proteinuria. Six of 10 treated and 3 of 12 untreated patients had remission of proteinuria to &lt;0.3 g/24 hours. Preliminary data in patients treated with
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         or
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          adefovir
         </a>
         also showed a benefit in kidney outcome [
         <a href="#rid47">
          47
         </a>
         ]. There are anecdotal data on the efficacy of lamivudine in HBV-associated MPGN [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of 10 studies (including four randomized, controlled trials) involving 325 patients evaluated the efficacy of nucleoside/nucleotide monotherapy in patients with HBV-associated glomerulonephritis [
         <a href="#rid48">
          48
         </a>
         ]. Of the 10 studies, five evaluated
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         , four evaluated
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         , and one evaluated
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          adefovir
         </a>
         . Treatment with nucleoside/nucleotide monotherapy was associated with higher rates of proteinuria remission to &lt;0.3 g/24 hours, disappearance of HBV DNA, and clearance of HBeAg. All the patients included in the meta-analysis were from Asia, and therefore, the generalizability of these results to other patient populations or nonendemic areas is unclear.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19584908">
         <span class="h3">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both interferon alfa and nucleoside/nucleotide analogs have been used to treat patients with HBV-associated kidney disease. In general, we prefer pegylated interferon (PegIFN) alfa-2a in children and young adults since clinical studies in these populations have shown efficacy in inducing remission of HBV-related glomerulonephritis [
         <a href="#rid49">
          49
         </a>
         ]. However, we generally avoid the use of interferon in patients who present with RPGN. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Nucleos(t)ide analogs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">
          "Management of hepatitis B virus infection in children and adolescents"
         </a>
         and
         <a class="local">
          'Rapidly progressive glomerulonephritis (RPGN)'
         </a>
         below.)
        </p>
        <p>
         Interferon is less well tolerated but is more likely to induce a sustained remission. Thus, it should be considered in children and young adults who can better tolerate interferon or who do not want to be on prolonged nucleoside/nucleotide therapy. We prefer PegIFN, which has superseded standard interferon in the treatment of chronic hepatitis B, although it has not been studied in patients with HBV-associated kidney disease. The dose of PegIFN should be adjusted according to kidney function (PegIFN alfa-2a should be dosed as 135 mcg/week if the estimated glomerular filtration rate [eGFR] is &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ). Additional information on the use of interferon for the treatment of chronic HBV is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3661.html" rel="external">
          "Pegylated interferon for treatment of chronic hepatitis B virus infection"
         </a>
         .)
        </p>
        <p>
         We prefer nucleoside/nucleotide analogs rather than interferon in older adults and patients who are not candidates for interferon therapy, regardless of age. As an example, interferon should be avoided in patients with cirrhosis  (
         <a class="graphic graphic_table graphicRef58520" href="/z/d/graphic/58520.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Antiviral therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3661.html" rel="external">
          "Pegylated interferon for treatment of chronic hepatitis B virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7354.html" rel="external">
          "Kidney transplantation in adults: Hepatitis B virus infection in kidney transplant recipients"
         </a>
         .)
        </p>
        <p>
         When a nucleoside/nucleotide analog is used,
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         or tenofovir is preferred in view of their antiviral efficacy, low propensity for drug resistance, and safety profiles. The dose of nucleoside/nucleotide analog often needs to be reduced in patients with impaired kidney function  (
         <a class="graphic graphic_table graphicRef71024" href="/z/d/graphic/71024.html" rel="external">
          table 2
         </a>
         ). If tenofovir is used, we generally prefer
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         to
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         because it is associated with a lower risk of kidney toxicity and can be used in patients with impaired kidney function with an eGFR &gt;15 mL/min/1.73 m
         <sup>
          2
         </sup>
         [
         <a href="#rid50">
          50,51
         </a>
         ]. By contrast, we try to avoid tenofovir disoproxil fumarate in patients with reduced kidney function, given the potential risk of additional kidney injury.
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          Adefovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9488" href="/z/d/drug information/9488.html" rel="external">
          telbivudine
         </a>
         are not preferred due to a high rate of resistance after the first year and/or weak antiviral activity. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p>
         If initial therapy with interferon is ineffective or not well tolerated, we will switch to a nucleoside/nucleotide analog. Conversely, if initial therapy with a nucleoside/nucleotide analog fails, we will consider a course of interferon.
        </p>
        <p class="headingAnchor" id="H85042544">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving interferon therapy receive a finite duration of therapy. The optimal duration of therapy for the oral drugs is not well established. Most patients receiving nucleoside/nucleotide analog therapy will require at least four to five years of treatment, and many require an indefinite duration of treatment  (
         <a class="graphic graphic_table graphicRef58520" href="/z/d/graphic/58520.html" rel="external">
          table 1
         </a>
         ). The administration of immunosuppressive therapy, if indicated, may also impact the duration of therapy (see
         <a class="local">
          'Immunosuppression and plasmapheresis in select patients'
         </a>
         below). More detailed discussions of the duration of antiviral therapy for patients with chronic HBV are presented elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Duration and treatment endpoints'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1341133">
         <span class="h2">
          Immunosuppression and plasmapheresis in select patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with HBV-associated kidney disease, treatment with antiviral therapy alone is sufficient. However, immunosuppression, with or without plasmapheresis, in combination with antiviral therapy may be beneficial in patients who have:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RPGN
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PAN with severe manifestations
        </p>
        <p>
        </p>
        <p>
         Except for these two indications, data from most observational studies suggest that immunosuppressive therapy with glucocorticoids or cytotoxic agents and plasmapheresis are of little benefit and are potentially harmful. This is particularly true among children with membranous nephropathy in whom spontaneous recovery over 6 to 24 months is common [
         <a href="#rid1">
          1,2,29
         </a>
         ]. Antiviral monotherapy may also be sufficient to treat HBV-associated PAN in patients who do not have severe or life-threatening disease [
         <a href="#rid42">
          42-44
         </a>
         ]. In addition, immunosuppressive therapy can trigger an increase in viral replication and possibly lead to exacerbation of chronic hepatitis [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p>
         There may be a potential role for immunosuppressive agents in the treatment of refractory cases of HBV-associated membranous nephropathy. In one report of two adult patients with HBV-associated membranous nephropathy, positive phospholipase A2 receptor (PLA2R) staining on kidney biopsy, anti-PLA2R seropositivity, and persistent proteinuria despite effective suppression of HBV DNA with
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         , the addition of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         led to remission of proteinuria and disappearance of anti-PLA2R [
         <a href="#rid55">
          55
         </a>
         ]. The authors postulated that HBV was the trigger of autoimmunity leading to anti-PLA2R-mediated membranous nephropathy. Another report described the clinical course of a patient with MPGN whose proteinuria did not improve despite seven months of entecavir treatment but responded to the addition of
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         [
         <a href="#rid56">
          56
         </a>
         ]. The generalizability of this sequential therapeutic approach remains to be established.
        </p>
        <p>
         Immunosuppressive treatment
         <strong>
          must always be
         </strong>
         accompanied by antiviral therapy since it may lead to increased viral replication and a flare of hepatitis [
         <a href="#rid57">
          57
         </a>
         ]. The type of immunosuppressive treatment may also impact the duration of antiviral therapy.
        </p>
        <p class="headingAnchor" id="H19585728">
         <span class="h3">
          Rapidly progressive glomerulonephritis (RPGN)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In rare patients with RPGN with extensive crescentic disease, presumed to be due to HBV infection, we suggest both antiviral medication (preferably a nucleoside/nucleotide analog) and a short course of high-dose glucocorticoids with or without an immunosuppressant, such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . The glucocorticoid regimen consists of intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , 500 to 1000 mg/day for up to three days, followed by
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , 0.7 to 1 mg/kg per day, tapered over four to six months. We generally avoid the use of interferon in these patients, given the lack of data on efficacy and the theoretical possibility that interferon could stimulate the immune response involved in crescent formation. (See
         <a class="medical medical_review" href="/z/d/html/3069.html" rel="external">
          "Mechanisms of glomerular crescent formation"
         </a>
         .)
        </p>
        <p>
         Antiviral therapy and monitoring of HBV DNA levels are continued for at least six months after cessation of immunosuppressive therapy (or at least 12 months if an anti-CD20 antibody is used) or until the therapeutic goal for hepatitis B is achieved. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Duration and treatment endpoints'
         </a>
         .)
        </p>
        <p>
         The treatment of RPGN associated with mixed cryoglobulinemia and HBV infection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis", section on 'Hepatitis B infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19585735">
         <span class="h3">
          Polyarteritis nodosa (PAN)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with mild PAN, we suggest antiviral therapy alone. However, in patients with PAN and severe manifestations (defined by the presence of ulcerative or gangrenous lesions of the extremities, acute kidney injury [AKI], polyneuropathy, central nervous system involvement, mesenteric arteritis, or myocardial ischemia), we suggest both glucocorticoids and plasmapheresis in addition to antiviral therapy (preferably a nucleoside/nucleotide analog). (See
         <a class="local">
          'Choice of therapy'
         </a>
         above.)
        </p>
        <p>
         The glucocorticoid and plasmapheresis regimens that we use are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         0.7 to 1 mg/kg per day, tapered over four to six months
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma exchange, 2.5 to 4 liters per session for a total of 6 to 10 sessions, daily or on alternate days, over two to three weeks
        </p>
        <p>
        </p>
        <p>
         As with RPGN, antiviral therapy and monitoring of HBV DNA levels are continued for at least six months after cessation of immunosuppressive therapy or until the therapeutic goal for hepatitis B is achieved, whichever is longer. (See
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Duration and treatment endpoints'
         </a>
         .)
        </p>
        <p>
         Although the data supporting the use of plasma exchange are weak, immunosuppression and plasma exchange are part of published treatment protocols for HBV-associated PAN [
         <a href="#rid34">
          34,42-44,58-62
         </a>
         ]. Glucocorticoids suppress the inflammatory component of the vasculitis [
         <a href="#rid29">
          29,34
         </a>
         ] and may improve survival [
         <a href="#rid63">
          63
         </a>
         ], although they can enhance viral replication and lead to exacerbation of chronic hepatitis. Plasmapheresis removes circulating immune complexes, which may be beneficial in patients with severe disease manifestations.
        </p>
        <p>
         The benefits of treating HBV-associated PAN with immunosuppression and plasmapheresis in combination with antiviral therapy were shown in a retrospective series of 80 patients with HBV-associated PAN who were treated with an antiviral agent (vidarabine, interferon alfa, or
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         , depending upon the era), a two-week course of glucocorticoids, and an intensive schedule of plasma exchange [
         <a href="#rid64">
          64
         </a>
         ]. Their clinical course and outcomes were compared with 35 historic controls (before the antiviral era) treated with glucocorticoids with or without
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , with most receiving plasma exchange. The following observations were made:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Remission was attained by 81 percent of all patients; patients who did not achieve remission died within a mean of 178 days. Overall five-year survival was 73 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At a median of 237 months, combination therapy with antivirals, immunosuppression, and plasmapheresis was associated with lower rates of relapse (4 versus 14 percent) and death (30 versus 49 percent), although the differences did not reach statistical significance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combination therapy was associated with a significantly higher rate of HBeAg seroconversion to anti-HBe (49 versus 15 percent), which predicted a sustained remission. Seroconversion rates were similar for interferon and
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         (both over 60 percent) but lower for vidarabine (41 percent), which is no longer used due to neurotoxicity.
        </p>
        <p>
        </p>
        <p>
         The addition of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         to glucocorticoids and plasma exchange does not appear to improve long-term outcomes in HBV-associated PAN, although it may contribute to more rapid control of disease [
         <a href="#rid58">
          58,64
         </a>
         ]. There are no data on the role of other immunosuppressive agents, including
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , in the treatment of HBV-associated PAN [
         <a href="#rid65">
          65,66
         </a>
         ], although some clinicians may choose to use one of these agents to spare the use of glucocorticoids. Although there are case reports on the efficacy of
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         in refractory or relapsing PAN, there are no data to support their use in HBV-associated PAN [
         <a href="#rid67">
          67,68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19585245">
         <span class="h1">
          PATIENTS WITH CONCOMITANT HCV INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients with concomitant hepatitis C virus (HCV) infection is complex. The choice of therapy depends upon the state of viral replication of the two viruses. HBV DNA and HCV RNA levels should be measured to determine if patient has HCV viremia.
        </p>
        <p>
         In patients with HBV and HCV coinfection (HCV RNA detected) and glomerulonephritis, initial therapy typically consists of the combination of direct-acting antivirals for treatment of HCV plus nucleoside/nucleotide analogs to treat HBV [
         <a href="#rid69">
          69
         </a>
         ]. Although interferon may seem like the logical therapeutic choice since it is active against both viruses, treatment of HCV with direct-acting antivirals is better tolerated and associated with higher rates of sustained virologic response and remission of glomerulonephritis associated with HCV cryoglobulinemia. However, direct-acting antivirals for treatment of HCV may lead to reactivation of HBV in patients who are hepatitis B surface antigen (HBsAg) positive and in such patients should be used together with nucleoside/nucleotide analogs for treatment of HBV. (See
         <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">
          "Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'HBV coinfection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">
          "Overview of kidney disease associated with hepatitis C virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">
          "Hepatitis B virus: Clinical manifestations and natural history", section on 'Coinfection with HCV or HDV'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2799869275">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">
          "Society guideline links: Glomerular disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Infection with hepatitis B virus (HBV) may be associated with a variety of kidney diseases. The three most common types of kidney disease resulting from HBV infection are membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), and polyarteritis nodosa (PAN). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of HBV-associated kidney disease should be considered in:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with acute or chronic HBV infection, particularly those from endemic areas, who present with clinical and/or laboratory features suggestive of glomerular disease (eg, proteinuria and/or hematuria, acute kidney injury [AKI] or deterioration in kidney function, with or without hypertension and/or edema). A kidney biopsy is often required to confirm the presence of an underlying glomerular process, although a different tissue site may be biopsied to confirm PAN.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with unknown HBV status who are found on kidney biopsy to have histologic evidence of membranous nephropathy, MPGN, or PAN. Such patients should be tested for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). If positive, additional testing for hepatitis B e antigen (HBeAg) and HBV DNA should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A presumptive diagnosis of HBV-associated kidney disease can be made in patients with biopsy-proven membranous nephropathy, MPGN, or PAN whose serologic tests show circulating HBsAg, particularly if the patient is a child from an endemic area or an adult without another identifiable cause for the kidney disease. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral therapy
         </strong>
         – For patients with presumed HBV-associated kidney disease and detectable serum HBV DNA or positive HbeAg, we recommend antiviral therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Indications for antiviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For most children and young adults, we suggest initial therapy with interferon alfa (usually pegylated interferon [PegIFN] alfa) rather than nucleoside/nucleotide analogs if there are no contraindications (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Interferon is less well tolerated but is more likely to induce a sustained remission.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For older adults and in patients with contraindications to interferon alfa (eg, cirrhosis), we suggest initial therapy with nucleoside/nucleotide analogs rather than interferon (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          Entecavir
         </a>
         or
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         is preferred. The dose of most nucleoside/nucleotide analogs needs to be reduced in patients with impaired kidney function  (
         <a class="graphic graphic_table graphicRef71024" href="/z/d/graphic/71024.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The duration of therapy depends upon the type of drug used and the patient's serologic response to therapy. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunosuppression and plasmapheresis in select patients
         </strong>
         – For most patients with HBV-associated kidney disease, treatment with antiviral therapy alone is sufficient. Immunosuppressive therapy with glucocorticoids or cytotoxic agents and plasmapheresis are of little benefit and are potentially harmful. However, immunosuppression (with or without plasmapheresis) in combination with antiviral therapy may be beneficial in select patients with severe clinical manifestations (see
         <a class="local">
          'Immunosuppression and plasmapheresis in select patients'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with rapidly progressive glomerulonephritis (RPGN) due to HBV infection, we suggest immunosuppression
         <strong>
          in addition to
         </strong>
         antiviral medication (preferably a nucleoside/nucleotide analog) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In such cases, we usually treat with a short course of glucocorticoids with or without an immunosuppressant, such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . (See
         <a class="local">
          'Rapidly progressive glomerulonephritis (RPGN)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with PAN and severe manifestations (defined by the presence of ulcerative or gangrenous lesions of the extremities, AKI, polyneuropathy, central nervous system involvement, mesenteric arteritis, or myocardial ischemia), we suggest immunosuppression
         <strong>
          in addition to
         </strong>
         antiviral medication (preferably a nucleoside/nucleotide analog) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In such cases, we usually treat with both glucocorticoids and plasmapheresis. (See
         <a class="local">
          'Polyarteritis nodosa (PAN)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with concomitant HCV infection
         </strong>
         – The management of patients with concomitant hepatitis C virus (HCV) infection is complex. The choice of therapy depends upon the state of viral replication of the two viruses. HBV DNA and HCV RNA levels should be measured to help determine the approach to treatment. If HCV RNA is detected, direct-acting antivirals should be administered for treatment of hepatitis C along with antiviral therapy for hepatitis B to prevent HBV reactivation. (See
         <a class="local">
          'Patients with concomitant HCV infection'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Johnson RJ, Couser WG. Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai KN, Lai FM. Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int Suppl 1991; 35:S40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupin WL. Viral-Associated GN: Hepatitis B and Other Viral Infections. Clin J Am Soc Nephrol 2017; 12:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Chen N. Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int Suppl 1991; 35:S24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu H, Sun L, Zhou LJ, et al. The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatr Nephrol 2003; 18:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao MT, Chang MH, Lin FG, et al. Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy. Pediatrics 2011; 128:e600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takekoshi Y, Tochimaru H, Nagata Y, Itami N. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl 1991; 35:S34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai KN, Ho RT, Tam JS, Lai FM. Detection of hepatitis B virus DNA and RNA in kidneys of HBV related glomerulonephritis. Kidney Int 1996; 50:1965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong L, Zhang J, Min J, et al. A role for MHBst167/HBx in hepatitis B virus-induced renal tubular cell apoptosis. Nephrol Dial Transplant 2010; 25:2125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diao Z, Ding J, Yin C, et al. Purified hepatitis B virus induces human mesangial cell proliferation and extracellular matrix expression in vitro. Virol J 2013; 10:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Wang L, Zhu N, et al. Hepatitis B virus X protein modulates renal tubular epithelial cell-induced T-cell and macrophage responses. Immunol Cell Biol 2016; 94:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Hu L, Zhu F, et al. Hepatitis B virus X protein promotes renal epithelial-mesenchymal transition in human renal proximal tubule epithelial cells through the activation of NF-κB. Int J Mol Med 2016; 38:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang Y, Wang X, Zhang Y, Yuan W. Hepatitis B virus X protein and proinflammatory cytokines synergize to enhance TRAIL-induced apoptosis of renal tubular cells by upregulation of DR4. Int J Biochem Cell Biol 2018; 97:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guan H, Zhu N, Tang G, et al. DNA methyltransferase 1 knockdown reverses PTEN and VDR by mediating demethylation of promoter and protects against renal injuries in hepatitis B virus-associated glomerulonephritis. Cell Biosci 2022; 12:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu L, Lin W, Shen C, et al. Intrarenal Single-Cell Sequencing of Hepatitis B Virus Associated Membranous Nephropathy. Front Med (Lausanne) 2022; 9:869284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung DR, Yang WS, Kim SB, et al. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. Am J Nephrol 1997; 17:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun IO, Hong YA, Park HS, et al. Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen. Ren Fail 2013; 35:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakai K, Morito N, Usui J, et al. Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection. Nephrol Dial Transplant 2011; 26:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou TB, Jiang ZP. Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report. Ren Fail 2015; 37:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha A, Theis JD, Vrana JA, et al. AA amyloidosis associated with hepatitis B. Nephrol Dial Transplant 2011; 26:2407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du Y, Zhang S, Hu M, et al. Association between hepatitis B virus infection and chronic kidney disease: A cross-sectional study from 3 million population aged 20 to 49 years in rural China. Medicine (Baltimore) 2019; 98:e14262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong YS, Ryu S, Chang Y, et al. Hepatitis B virus infection and development of chronic kidney disease: a cohort study. BMC Nephrol 2018; 19:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YC, Su YC, Li CY, Hung SK. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naïve patients with chronic hepatitis B in Taiwan. BMC Nephrol 2015; 16:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YC, Li CY, Tsai SJ, Chen YC. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection. World J Gastroenterol 2018; 24:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li P, Wei RB, Tang L, et al. Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Clin Nephrol 2012; 78:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie Q, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 2015; 41:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang R, Wu Y, Zheng B, et al. Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection. Sci Rep 2021; 11:18407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1998; 41:2100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995; 47:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez GO, Pardo V, Fletcher M. Renal involvement in essential mixed cryoglobulinemia. Am J Kidney Dis 1987; 10:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enríquez R, Sirvent AE, Andrada E, et al. Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection. Ren Fail 2010; 32:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li SJ, Xu ST, Chen HP, et al. Clinical and morphologic spectrum of renal involvement in patients with HBV-associated cryoglobulinaemia. Nephrology (Carlton) 2017; 22:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011) 2012; 2:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Zhou JH, Yin XL, Wang FY. Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis. World J Gastroenterol 2010; 16:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lisker-Melman M, Webb D, Di Bisceglie AM, et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann Intern Med 1989; 111:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conjeevaram HS, Hoofnagle JH, Austin HA, et al. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995; 109:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhimma R, Coovadia HM, Kramvis A, et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002; 17:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther 2006; 24:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen YK, Chen ML. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. Clin Nephrol 2006; 65:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruger M, Böker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997; 26:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avşar E, Savaş B, Tözün N, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998; 28:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone. J Clin Gastroenterol 1995; 20:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenderfer SE. Viral-associated glomerulopathies in children. Pediatr Nephrol 2015; 30:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun IO, Hong YA, Park HS, et al. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med 2012; 27:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang WN, Wu MY, Ma FZ, et al. Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis. Clin Nephrol 2016; 85:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yi Z, Jie YW, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis. Ann Hepatol 2011; 10:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CY, Lo SC. Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int 1991; 39:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990; 54:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sayarlioglu H, Erkoc R, Dogan E, et al. Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication. Ann Pharmacother 2005; 39:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berchtold L, Zanetta G, Dahan K, et al. Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy. Kidney Int Rep 2018; 3:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kataoka H, Mochizuki T, Akihisa T, et al. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report. Medicine (Baltimore) 2019; 98:e14014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013; 310:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 2003; 7:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wicki J, Olivieri J, Pizzolato G, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) 1999; 38:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen HL, van Zonneveld M, van Nunen AB, et al. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol 2004; 16:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int 2012; 32:2215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Néel A, Masseau A, Hervier B, et al. Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab. J Clin Rheumatol 2011; 17:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krusche M, Ruffer N, Kötter I. Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature. Rheumatol Int 2019; 39:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang CR, Yang CC. Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report. Medicine (Baltimore) 2018; 97:e11053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62:932.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3119 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1968522" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1770709" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27797900" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Viral-Associated GN: Hepatitis B and Other Viral Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1770708" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14586681" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21859911" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1837572" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2023605" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Membranous nephropathy related to hepatitis B virus in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8943480" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Detection of hepatitis B virus DNA and RNA in kidneys of HBV related glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20118485" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A role for MHBst167/HBx in hepatitis B virus-induced renal tubular cell apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24093684" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Purified hepatitis B virus induces human mesangial cell proliferation and extracellular matrix expression in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26365016" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hepatitis B virus X protein modulates renal tubular epithelial cell-induced T-cell and macrophage responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27314843" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hepatitis B virus X protein promotes renal epithelial-mesenchymal transition in human renal proximal tubule epithelial cells through the activation of NF-κB.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29432906" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hepatitis B virus X protein and proinflammatory cytokines synergize to enhance TRAIL-induced apoptosis of renal tubular cells by upregulation of DR4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35765066" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : DNA methyltransferase 1 knockdown reverses PTEN and VDR by mediating demethylation of promoter and protects against renal injuries in hepatitis B virus-associated glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35935760" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intrarenal Single-Cell Sequencing of Hepatitis B Virus Associated Membranous Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9096440" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23506536" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20959346" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25585950" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21543651" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : AA amyloidosis associated with hepatitis B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30702585" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Association between hepatitis B virus infection and chronic kidney disease: A cross-sectional study from 3 million population aged 20 to 49 years in rural China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30537940" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hepatitis B virus infection and development of chronic kidney disease: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26199000" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : 13-year nationwide cohort study of chronic kidney disease risk among treatment-naïve patients with chronic hepatitis B in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29491685" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23164414" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26087695" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34526634" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9870866" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treatment of polyarteritis nodosa and microscopic polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7731150" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3310617" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Renal involvement in essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20446795" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27062412" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical and morphologic spectrum of renal involvement in patients with HBV-associated cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7565065" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25018935" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chapter 10: Immunoglobulin A nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20135728" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2774373" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7615204" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12107801" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of hepatitis B virus-associated nephropathy in black children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16918881" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16550753" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9126810" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9551696" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7797845" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25752759" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Viral-associated glomerulopathies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16164651" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lamivudine in hepatitis B-associated membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23269882" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26636326" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21502678" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28404091" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28404092" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2002643" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2296339" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15671086" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29725654" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30633192" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24150447" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : FDA: Increased HBV reactivation risk with ofatumumab or rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12918937" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Indications of plasma exchanges for systemic vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10342635" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7912504" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15188337" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15256984" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/42314" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Immunosuppressive and corticosteroid therapy of polyarteritis nodosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16148731" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21786122" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22089995" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30465270" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29923995" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26111063" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
